Alexion Continues to Diversify its Portfolio with Achillion Acquisition

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)

Published: 23 Oct-2019

DOI: 10.3833/pdr.v2019.i10.2464     ISSN: 1756-7874

Section: Mergers & Acquisitions



In a bid to build out its pipeline beyond Soliris® (eculizumab), Alexion Pharmaceuticals has agreed to acquire Achillion Pharmaceuticals for US$930 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details